The AI in Business Podcast

Drug discovery teams are running short of new ideas to test, and AI models that simulate how cells respond to drugs only pay off once leaders know when those predictions can be trusted with experiments, timelines, and budget.
 
In this episode, Daniel Veres, Co-Founder and Chief Scientific Officer at Turbine, and Giorgio Gaglia, Head of Systems and Disease Biology at Sanofi, examine with host Yolandi de Weerdt how testing models on data they have never seen shows which R&D decisions their predictions can reliably inform.
 
The discussion offers R&D leaders a practical way to judge when a model's predictions are ready to inform which experiments to run, where in the pipeline to start, and how much risk to accept.
 
This episode is sponsored by Turbine.
 
Learn how these conversations drive pipeline for other AI brands — download our media kit at emerj.com/AD1

In biopharma R&D, AI investment has overwhelmingly targeted generating more drug candidates, even though the industry has rarely lacked for compounds worth pursuing. In this episode, Mukhtar Ahmed, Director of Project and Portfolio Strategy at Greenstone Biosciences, explores why the harder and more valuable problem is deciding which candidates deserve continued capital and attention. The conversation covers synthesizing fragmented evidence across teams, keeping human judgment and accountability in the loop, and measuring AI's impact across a portfolio rather than a single program.
​
Emerj works with a select group of AI vendors to reach Fortune 500 decision-makers through research, media, and direct access. If you want to be considered, download our media kit at emerj.com/AD1

Finance teams face immense pressure to operate faster, but rushing to automate over fragmented systems only compounds errors downstream. Ciprian Porutiu, SVP of Strategic Initiatives at Marsh, joins host Yolandi de Weerdt to explain why establishing a common language and federated data domains matters far more than forcing everything into a single centralized database. He shares practical approaches for managing phased rollouts, involving cross-functional users early in system design, and connecting underlying data governance directly to strategic business performance.
​
This episode is sponsored by Fynapse. Learn how financial institutions are digitizing paper-based records to unlock usable data for AI, and using alternative data like public web and social signals to enhance risk assessment, download our free PDF report, "AI in Financial Services Executive Cheat Sheet" at emerj.com/fcs1

For large banks, the barrier to AI at scale is rarely the model. It's decades of fragmented systems, inherited through mergers, acquisitions, and new products, where each team trusts its own data and no single view of context exists. Agentic AI doesn't fix that fragmentation; it amplifies it across every user and every prompt.
​
In this episode, Nathaniel Bell, Data Management Director at Wells Fargo, joins host Yolandi de Weerdt,  to examine why the real challenge for regulated institutions is scaling trust while automating, why leaders should judge new technology on the business outcome it can prove rather than the demo, and why no process should be automated before it's standardized.
​
Bell outlines the practical shifts underway: from manual attestations and spreadsheets toward automated logs that show what happened in a workflow, from governance as document review toward governance built into workflows as code, and from buying new tools toward changing how teams work once they have them.
​
According to Nielsen, 91% of podcast listening happens alone, indicating deep, undistracted attention — ideal for complex B2B messaging.
​
To learn how leading brands and AI startups connect with enterprise AI buyer audiences at scale, download our media kit at emerj.com/AD1

Hospitals and clinics continue to face a central challenge: extensive cardiac testing still fails to deliver clear, consistent diagnostic answers, slowing decision‑making and creating downstream operational and financial strain.


In this episode, Jim Hartman, Chief Commercial Officer at Cleerly, examines with host Marilie Fouché how AI‑driven coronary CTA analysis strengthens diagnostic certainty, streamlines workflows across radiology, cardiology, and the cath lab, and supports more defensible adoption decisions for clinical and operational leaders.


The discussion highlights practical evaluation criteria — clinical impact, workflow efficiency, and financial return — that executives can use to assess whether advanced imaging technologies can be integrated and scaled within their organizations.


This episode is sponsored by Cleerly.
​
Learn how to identify AI trends by tracking where venture funding is flowing, and by listening to how leading CEOs describe risk and competitive strategy, download our free PDF report, "3 Ways to Discover AI Trends in Any Sector" at emerj.com/ait1